Cargando…
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals
In this paper we evaluate the economic gains of a joint deployment of femtocells and macrocells for the provision of Long Term Evolution (LTE) mobile broadband services in urban environments. Frequency bands of 2.6 GHz and 900 MHz are analyzed and different parameters related to the business model a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941829/ https://www.ncbi.nlm.nih.gov/pubmed/25928565 http://dx.doi.org/10.1186/gb-2012-13-3-1234 |
_version_ | 1783484605110681600 |
---|---|
author | Martinez, Valérie TA, Thi Dieu Ngan Mokhtari, Zahra Guiguet, Marguerite Miailhes, Patrick Valantin, Marc-Antoine Charlotte, Fréderic Bertheau, Philippe Molina, Jean-Michel Katlama, Christine Caumes, Eric |
author_facet | Martinez, Valérie TA, Thi Dieu Ngan Mokhtari, Zahra Guiguet, Marguerite Miailhes, Patrick Valantin, Marc-Antoine Charlotte, Fréderic Bertheau, Philippe Molina, Jean-Michel Katlama, Christine Caumes, Eric |
author_sort | Martinez, Valérie |
collection | PubMed |
description | In this paper we evaluate the economic gains of a joint deployment of femtocells and macrocells for the provision of Long Term Evolution (LTE) mobile broadband services in urban environments. Frequency bands of 2.6 GHz and 900 MHz are analyzed and different parameters related to the business model are considered for a 30% market share operator. Results show important benefits for the base case where the service is offered to fixed-broadband clients, up to 75%, for small bandwidths. It results feasible to attribute subscriber loop costs to the radio access network (RAN) costs, so that the service could be offered to non fixed-broadband clients, in both cases of closed access and open access femtocells. However, initial savings result notably reduced, up to 50% less than in the base case if closed access is adopted and up to 13% less for open access. Site reuse reduces the initial savings only in 3%. |
format | Online Article Text |
id | pubmed-6941829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69418292020-03-24 Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals Martinez, Valérie TA, Thi Dieu Ngan Mokhtari, Zahra Guiguet, Marguerite Miailhes, Patrick Valantin, Marc-Antoine Charlotte, Fréderic Bertheau, Philippe Molina, Jean-Michel Katlama, Christine Caumes, Eric Genome Biol Research In this paper we evaluate the economic gains of a joint deployment of femtocells and macrocells for the provision of Long Term Evolution (LTE) mobile broadband services in urban environments. Frequency bands of 2.6 GHz and 900 MHz are analyzed and different parameters related to the business model are considered for a 30% market share operator. Results show important benefits for the base case where the service is offered to fixed-broadband clients, up to 75%, for small bandwidths. It results feasible to attribute subscriber loop costs to the radio access network (RAN) costs, so that the service could be offered to non fixed-broadband clients, in both cases of closed access and open access femtocells. However, initial savings result notably reduced, up to 50% less than in the base case if closed access is adopted and up to 13% less for open access. Site reuse reduces the initial savings only in 3%. BioMed Central 2013-01-15 2012 /pmc/articles/PMC6941829/ /pubmed/25928565 http://dx.doi.org/10.1186/gb-2012-13-3-1234 Text en © Ascierto et al; licensee BioMed Central Ltd. 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Martinez, Valérie TA, Thi Dieu Ngan Mokhtari, Zahra Guiguet, Marguerite Miailhes, Patrick Valantin, Marc-Antoine Charlotte, Fréderic Bertheau, Philippe Molina, Jean-Michel Katlama, Christine Caumes, Eric Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals |
title | Hepatic steatosis in HIV-HCV coinfected patients receiving
antiretroviral therapy is associated with HCV-related factors but not
antiretrovirals |
title_full | Hepatic steatosis in HIV-HCV coinfected patients receiving
antiretroviral therapy is associated with HCV-related factors but not
antiretrovirals |
title_fullStr | Hepatic steatosis in HIV-HCV coinfected patients receiving
antiretroviral therapy is associated with HCV-related factors but not
antiretrovirals |
title_full_unstemmed | Hepatic steatosis in HIV-HCV coinfected patients receiving
antiretroviral therapy is associated with HCV-related factors but not
antiretrovirals |
title_short | Hepatic steatosis in HIV-HCV coinfected patients receiving
antiretroviral therapy is associated with HCV-related factors but not
antiretrovirals |
title_sort | hepatic steatosis in hiv-hcv coinfected patients receiving
antiretroviral therapy is associated with hcv-related factors but not
antiretrovirals |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941829/ https://www.ncbi.nlm.nih.gov/pubmed/25928565 http://dx.doi.org/10.1186/gb-2012-13-3-1234 |
work_keys_str_mv | AT martinezvalerie hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT tathidieungan hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT mokhtarizahra hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT guiguetmarguerite hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT miailhespatrick hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT valantinmarcantoine hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT charlottefrederic hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT bertheauphilippe hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT molinajeanmichel hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT katlamachristine hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals AT caumeseric hepaticsteatosisinhivhcvcoinfectedpatientsreceivingantiretroviraltherapyisassociatedwithhcvrelatedfactorsbutnotantiretrovirals |